Genome-wide association study for germline prognostic markers in colorectal cancer

Genome-wide association study for germline prognostic markers in colorectal cancer

Detalles Bibliográficos
Autores principales:	Walther, A, Domingo, E, Mesher, D, Johnstone, E, Orntoft, T, Sasieni, P, Dunlop, M, Tejpar, S, Kerr, D, Tomlinson, I, Grp, V, Grp, P
Formato:	Journal article
Publicado:	2010

Ejemplares similares

Genetic prognostic and predictive markers in colorectal cancer.
por: Walther, A, et al.
Publicado: (2009)

Erratum: Genetic prognostic and predictive markers in colorectal cancer (Nature Reviews Cancer (2009) 9 (489-499))
por: Walther, A, et al.
Publicado: (2011)

Effect of SNP haplotypes associated with colorectal cancer risk on outcome
por: Walther, A, et al.
Publicado: (2008)

Is sidedness prognostically important across all stages of colorectal cancer?
por: Kerr, D, et al.
Publicado: (2016)

Genetic prognostic markers in colorectal cancer.
por: Houlston, R, et al.
Publicado: (1997)

What is the role and impact of molecular markers on treatment decisions in the adjuvant setting of colorectal cancer?
por: Johnstone, E, et al.
Publicado: (2008)

REporting recommendations for tumor MARKer prognostic studies (REMARK)
por: McShane, L, et al.
Publicado: (2005)

REporting recommendations for tumor MARKer prognostic studies (REMARK)
por: McShane, L, et al.
Publicado: (2005)

Genome wide identification of novel DNA methylation driven prognostic markers in colorectal cancer
por: Yuhua Ma, et al.
Publicado: (2024-07-01)

Germline epimutations of APC are not associated with inherited colorectal polyposis.
por: Hitchins, M, et al.
Publicado: (2006)

VICTOR: A PHASE III PLACEBO-CONTROLLED TRIAL OF ROFECOXIB IN COLORECTAL CANCER PATIENTS FOLLOWING SURGICAL RESECTION
por: Midgley, R, et al.
Publicado: (2008)

Follow up after colorectal surgery (the FACS trial)
por: Corkhill, A, et al.
Publicado: (2004)

EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis
por: Kokko, A, et al.
Publicado: (2006)

Mutation burden and other molecular markers of prognosis in the QUASAR2 clinical trial of colorectal cancer treated with curative intent
por: Domingo, E, et al.
Publicado: (2018)

Germline genetic regulation of the colorectal tumor immune microenvironment
por: Stephanie L. Schmit, et al.
Publicado: (2024-04-01)

Germline HNPCC gene variants have little influence on the risk for sporadic colorectal cancer.
por: Tomlinson, I, et al.
Publicado: (1997)

GLR in Colorectal Cancers: An Easily Accessible Prognostic Marker
por: Aydin İC, et al.
Publicado: (2024-05-01)

Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer
por: Houlston, R, et al.
Publicado: (2008)

Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer.
por: Houlston, R, et al.
Publicado: (2008)

Frequency of germline hereditary non-polyposis colorectal cancer gene mutations in patients with multiple or early onset colorectal adenomas.
por: Beck, N, et al.
Publicado: (1997)

Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers.
por: Briggs, S, et al.
Publicado: (2013)

Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.
por: Palles, C, et al.
Publicado: (2013)

Genome-wide association study of germline variants and breast cancer-specific mortality
por: Escala-Garcia, M, et al.
Publicado: (2019)

QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients.
por: Gray, R, et al.
Publicado: (2004)

Prognostic value of p53, hMLH1, hMSH2, MGMT and COX-2 in the QUASAR-1 Dukes' stage B colorectal cancer cohort
por: Jubb, A, et al.
Publicado: (2002)

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
por: Kerr, R, et al.
Publicado: (2016)

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
por: Love, S, et al.
Publicado: (2016)

A detector for precision study of high energy e(+)e(-) annihilations: The ECFA/DESY design for TESLA
por: Burrows, P, et al.
Publicado: (2000)

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
por: Domingo, E, et al.
Publicado: (2013)

Germline determinants of colorectal cancer risk and outcome
por: Freeman-Mills, L
Publicado: (2017)

MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer.
por: Hitchins, M, et al.
Publicado: (2005)

Germline epigenetic silencing of the tumor suppressor gene PTPRJ in early-onset familial colorectal cancer.
por: Venkatachalam, R, et al.
Publicado: (2010)

Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer
por: Teo, M, et al.
Publicado: (2014)

Germline mutations but not somatic changes at the MYH locus contribute to the pathogenesis of unselected colorectal cancers.
por: Halford, SE, et al.
Publicado: (2003)

Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series
por: Domingo, E, et al.
Publicado: (2018)

A genome-wide scan of 10 000 gene-centric variants and colorectal cancer risk.
por: Webb, E, et al.
Publicado: (2009)

Germline deletions of EXO1 do not cause colorectal tumors and lesions which are null for EXO1 do not have microsatellite instability.
por: Alam, N, et al.
Publicado: (2003)

Genome-wide allelotyping of 104 Finnish colorectal cancers reveals an excess of allelic imbalance in chromosome 20q in familial cases.
por: Laiho, P, et al.
Publicado: (2003)

Comprehensive assessment of variation at the transforming growth factor beta type 1 receptor locus and colorectal cancer predisposition.
por: Carvajal-Carmona, L, et al.
Publicado: (2010)

PROGNOSTIC MARKERS FOR THROMBOTIC EVENTS IN PATIENTS WITH GASTRIC OR COLORECTAL ADENOCARCINOMAS
por: Emilly de Assis MACHADO, et al.
Publicado: (2024-12-01)